Related Experiment Video

Updated: Jun 12, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Targeted therapy in inflammatory breast cancer

Hideko Yamauchi1, Naoto T Ueno

  • 1Department of Breast Surgical Oncology, St Luke's International Hospital, Tokyo, Japan.

Cancer
|May 27, 2010
PubMed

Insights

Inflammatory breast cancer (IBC) has a poor prognosis despite current treatments. Molecular targeted therapies, particularly those targeting human epidermal growth factor receptor 2 (HER-2) and epidermal growth factor receptor (EGFR), show promise for improving outcomes in IBC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Inflammatory breast cancer (IBC) presents a significant clinical challenge with a generally poor prognosis, even with multimodality treatment.
  • Recent advancements in molecular targeted therapies offer potential new avenues for treating IBC.

Purpose of the Study:

  • To review the current literature on molecular targets and targeted therapies for inflammatory breast cancer.
  • To identify promising therapeutic targets and strategies for improving IBC patient outcomes.

Main Methods:

  • Literature review of studies investigating molecular targets and targeted therapies in IBC.
  • Analysis of clinical trial data for HER-2 targeted agents (trastuzumab, lapatinib).
  • Examination of other potential molecular targets including WNT1, Ras homolog gene family member C, EGFR, p27(kip1), and E-cadherin.

Main Results:

  • Trastuzumab and lapatinib show efficacy in HER-2-positive breast cancers, suggesting potential for IBC.
  • Molecular targets involved in vasculolymphatic processes (angiogenesis, lymphangiogenesis, vasculogenesis) appear more relevant in IBC than non-IBC.
  • Paradoxical overexpression of E-cadherin in IBC, despite its association with epithelial-to-mesenchymal transition, warrants further investigation.

Conclusions:

  • Targeted therapies, especially those against HER-2 and potentially EGFR, represent a promising direction for IBC treatment.
  • Understanding the unique molecular mechanisms driving IBC aggressiveness, such as E-cadherin overexpression, is crucial for developing innovative therapies.
  • Further research into EGFR's role may lead to novel targeted therapeutic strategies for inflammatory breast cancer.

More Related Videos

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells05:02

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...